Recent

% | $
Quotes you view appear here for quick access.

Geron Corporation (GERN) Message Board

  • end2war end2war Jul 9, 2014 6:43 PM Flag

    It might interest some to know that GERN Director, Daniel Bradbury is the President and CEO Amylin Pharmaceuticals Inc

    Amylin Pharmaceuticals Inc was acquired by Bristol Myers Squib for $5.3 Billion in 2012. Bradbury is the one that was buying GERN stock in the open market recently.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • They know GERN is the future.

      Sentiment: Strong Buy

    • He certainly has a lot of contacts and experience in the industry. Seems that he is happy clipping coupons and taking professional BOD fees at the present.
      Illumina Inc
      Director Compensation for 2013
      Fees earned or paid in cash $78,538
      Stock awards $177,725
      Option awards (in $) $224,305
      Total Compensation $480,568
      Stock Ownership for 2014
      Number of shares owned 12,466
      Corcept Therapeutics Inc
      Director Compensation for 2013
      Fees earned or paid in cash $39,500
      Option awards (in $) $43,573
      Total Compensation $83,073
      Geron Corp
      Director Compensation for 2013
      Fees earned or paid in cash $55,000
      Option awards (in $) $24,875
      Total Compensation $79,875
      Stock Ownership for 2014
      Number of shares owned 142,776
      BioMed Realty Trust Inc
      Director Compensation for 2013
      Fees earned or paid in cash $71,500
      Stock awards $160,001
      Total Compensation $231,501
      Stock Ownership for 2014
      Number of shares owned 11,658
      Transcept Pharmaceuticals, Inc.
      Stock Ownership for 2006
      Number of shares owned 35,714

    • END , Thanks again.

    • Let's hope he was putting smart money in play and not taking a long shot gamble with excess riches not fully appreciated by those vaulted to an unfamiliar heady level of richness. On another topic: the FDA is the epitome of America's successful corruption of character. Innovation is better served these days in Eastern Bygonia on the upper reaches of the Congo headwaters. .

      woofs

    • end - Don't know if this means anything. May 27, 2014 -- Bristol-Myers Squibb Company (NYSE: BMY) and Incyte Corporation (Nasdaq: INCY) announced today the establishment of a clinical trial collaboration to evaluate the safety, tolerability and preliminary efficacy of a combination regimen of Bristol-Myers Squibb’s investigational PD-1 immune checkpoint inhibitor, nivolumab, and Incyte’s oral indoleamine dioxygenase-1 (IDO1) inhibitor, INCB24360, in a Phase I/II
      trial. This is not an MF or blood cancer trial. And I know nothing - just found this in my research.

      • 3 Replies to irishtrader52
      • They know GERN in going to make medical history.

        Sentiment: Strong Buy

      • Irish your post this morning was pulled...not sure what it was but saw your name remaining on the sequenced message roster. Curious if it pertained to this. Seems like such a wasted effort given the potential here, unless of course there had been other plans in the works bfr. the hold.

      • Irish, I have read about "check point inhibitors". These are defenses that cancers have to evade the bodies immune system. The Pd1 pathway is one of the first discovered, I believe. (There are about a dozen others that have been discovered.) Check point inhibitor drugs are thought to be very promising part of immunotherapy. They can be thought of as poles that cancer sticks out to keep hidden from the immune system agents that are looking for the cancer.

        A lot of promising work on cancer focuses on boosting the killer T8 cells attack on the cancer; and to do this, check point inhibitor drugs are used in combination with vaccines and other immune boosters to help the killer T8 cells find and kill cancer cells.

        Since Imetestat is not an immunotherapy, it is doubtful they would use a "check point inhibitor" drug in combination with Imetestat (unless they thought, perhaps, that cancer was evading the attack on telomerase inhibition in some way that these new drugs could block).

        One thing is clear, Bradbury is a leader working on very cutting edge stuff at BMS and it is impressive to me that a person of his knowledge has made a large insider bet on telomerase inhibition. I expect this guy is super qualified as a cancer expert. He is an insider to be respected. IMO. I think the shorts should take note that his largest stock pick, making up 70% of his Form 4 disclosures, is GERN!

    • endo,
      No buyout-in near future IMO !

      Vette

      Sentiment: Strong Buy

    • Good to know!! Thanks.

 
GERN
3.85-0.01(-0.26%)12:32 PMEDT